ArticleCPT: pharmacometrics & systems pharmacology2023

PK/PD model-informed dose selection for oncology phase I expansion: Case study based on PF-06939999, a PRMT5 inhibitor.

Cen Guo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.